clinical trial · NCT07435129
Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD
Scholar Rock, Inc.·phase2·not yet recruiting·n = 60
Facioscapulohumeral Muscular DystrophyFSHDApitegromabPlacebo
brief summary
A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD
started
Aug 1, 2026
primary completion
Jun 1, 2028
completion
Dec 1, 2028
last updated
Feb 27, 2026
detailed description
This Phase 2, randomized, double-blind, placebo-controlled, multicenter study is designed to evaluate the efficacy, safety, and tolerability of apitegromab in participants with facioscapulohumeral muscular dystrophy (FSHD)
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the Efficacy and Safety of Apitegromab in Participants With Facioscapulohumeral Muscular Dystrophy (FORGE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol